Inventor
ZHENG PAN
US30 patents
⚠️ This page may combine multiple inventors who share the name “ZHENG PAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ONCOIMMUNE INC
9 patentsUS10618960B2Apr 14, 2020
Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
ONCOIMMUNE INC12 citations84
US10793617B2Oct 6, 2020
Methods of use of soluble CD24 for therapy of rheumatoid arthritis
ONCOIMMUNE INC1 citations71
US9611309B2Apr 4, 2017
Methods of use of soluble CD24 for therapy of rheumatoid arthritis
ONCOIMMUNE INC2 citations71
US11911441B2Feb 27, 2024
Methods of use of CD24 for the prevention and treatment of leukemia relapse
ONCOIMMUNE INC0 citations61
US11571461B2Feb 7, 2023
Methods of use of soluble CD24 for treating lupus nephritis
ONCOIMMUNE INC0 citations61
US8895022B2Nov 25, 2014
Methods of use of soluble CD24 for therapy of rheumatoid arthritis
ONCOIMMUNE INC2 citations61
US11547741B2Jan 10, 2023
Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies
ONCOIMMUNE INC0 citations60
US10799558B2Oct 13, 2020
Use of CD24 proteins for treating leptin-deficient conditions
ONCOIMMUNE INC0 citations51
US9877998B2Jan 30, 2018
Uses of hypoxia-inducible factor inhibitors
ONCOIMMUNE INC0 citations49
ONCOC4 INC
7 patentsUS11261233B2Mar 1, 2022
CD80 and CD86 binding protein compositions and uses thereof
ONCOC4 INC6 citations83
US12227557B2Feb 18, 2025
CD80 and CD86 binding protein compositions and uses thereof
ONCOC4 INC2 citations72
US12473362B2Nov 18, 2025
Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
ONCOC4 INC0 citations61
US11629188B2Apr 18, 2023
Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
ONCOC4 INC0 citations61
US12441780B2Oct 14, 2025
CD80 and CD86 binding protein compositions and uses thereof
ONCOC4 INC0 citations60
US12129299B2Oct 29, 2024
Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
ONCOC4 INC0 citations60
US12286485B2Apr 29, 2025
Anti-CD24 compositions and uses thereof
ONCOC4 INC0 citations50
LIU YANG
5 patentsUS7744894B2Jun 29, 2010
Method of treating multiple sclerosis and related t-cell initiated tissue destruction by administering HSA/CD24
LIU YANG4 citations61
US8163281B2Apr 24, 2012
Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
LIU YANG4 citations58
US8158596B2Apr 17, 2012
Materials and methods for FOXP3 tumor suppression
LIU YANG2 citations58
US9427413B2Aug 30, 2016
Uses of hypoxia-inducible factor inhibitors
LIU YANG0 citations50
US8637013B2Jan 28, 2014
Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
LIU YANG0 citations48
UNIV OHIO STATE RES FOUND
3 patentsUS7504554B2Mar 17, 2009
Animal model for identifying agents that inhibit or enhance CTLA4 signaling
UNIV OHIO STATE RES FOUND9 citations82
US7161058B2Jan 9, 2007
Animal model for identifying agents that inhibit or enhance CTLA4 signaling
UNIV OHIO STATE RES FOUND5 citations71
US6875904B2Apr 5, 2005
Animal model for identifying agents that inhibit or enhance CTLA4 signaling
UNIV OHIO STATE RES FOUND8 citations71
ONCOLMMUNE INC
3 patentsUS10369197B2Aug 6, 2019
Use of CD24 for lowering low-density lipoprotein cholesterol levels
ONCOLMMUNE INC3 citations71
US11026995B2Jun 8, 2021
Use of CD24 for lowering low-density lipoprotein cholesterol levels
ONCOLMMUNE INC1 citations60
US9623070B2Apr 18, 2017
Uses of hypoxia-inducible factor inhibitors
ONCOLMMUNE INC0 citations48